UBS Group
PACB icon

UBS Group’s Pacific Biosciences PACB Stock Holding History

UBS Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-749,100
Closed -$8.67M – 9450
2023
Q1 		$8.67M Buy
+749,100
New +$7.45M ﹤0.01% 1996

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's PACB Position: Q2 2026 in Review

UBS Group reduced its Pacific Biosciences (PACB) stake by 46% in Q2 2026, selling an estimated $1.09M and leaving 893,140 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #5365.

UBS Group first reported a position in PACB in Q4 2014 and has held it in 47 quarters since. The position peaked at $22.1M in Q4 2016. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • UBS Group held 893,140 shares of Pacific Biosciences worth $1.5M as of Q2 2026.
  • UBS Group sold 746,959 Pacific Biosciences shares in Q2 2026, an estimated $1.09M.
  • Pacific Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5365 holding.
  • UBS Group first reported a position in Pacific Biosciences in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Pacific Biosciences position peaked at $22.1M in Q4 2016.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.